Fulzerasib: First Approval.

Area of Science:

• Oncology
• Pharmacology

Background:

• Fulzerasib is an orally active small molecule inhibitor targeting the KRAS G12C mutant protein.
• This mutation is a key driver in various solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer.

Purpose of the Study:

• To summarize the development milestones of fulzerasib.
• To document the drug's first approval for treating KRAS G12C-mutated advanced NSCLC.

Main Methods:

• Review of clinical development data for fulzerasib.
• Analysis of the phase II study results supporting the drug's efficacy.

Main Results:

• Fulzerasib received its first conditional approval in China on August 21, 2024.
• Approval is for adults with KRAS G12C-mutated advanced NSCLC after at least one line of systemic therapy.

Conclusions:

• Fulzerasib represents a significant advancement in targeted therapy for KRAS G12C-mutated NSCLC.
• The drug's development highlights progress in precision medicine for oncological conditions.